Biosplice Therapeutics, Inc.
Clinical trials sponsored by Biosplice Therapeutics, Inc., explained in plain language.
-
One-Shot knee injection could ease arthritis pain for over a year
Disease control CompletedThis study tested a single injection of a drug called lorecivivint in the knee joint of 501 people with moderate to severe knee osteoarthritis. The goal was to see if it reduces pain and improves function over 56 weeks compared to a placebo. Participants were adults aged 40-80 wi…
Phase: PHASE3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 09:30 UTC
-
One shot to ease knee pain? new study tests lorecivivint
Symptom relief CompletedThis study tested a single injection of lorecivivint in the knee joint of 496 adults with moderate to severe knee osteoarthritis. The goal was to see if it reduces pain and improves function compared to a placebo over 28 weeks. Participants reported their pain levels weekly using…
Phase: PHASE3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated May 18, 2026 12:10 UTC
-
New knee shot shows promise for osteoarthritis sufferers
Symptom relief CompletedThis study tested an experimental drug called SM04690, given as two injections into the knee about six months apart, in 101 people with moderate to severe knee osteoarthritis. The main goal was to check safety and measure changes in bone density in the treated knee compared to a …
Phase: PHASE2 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated May 15, 2026 11:57 UTC